Forma Therapeutics, Inc.

United States of America


 
Total IP 157
Total IP Rank # 8,258
IP Activity Score 2.8/5.0    94
IP Activity Rank # 7,389
Parent Entity Forma Therapeutics Holdings LLC
Dominant Nice Class Scientific, technological and in...

Patents

Trademarks

74 6
10 0
66 0
1
 
Last Patent 2025 - Inhibiting mutant isocitrate deh...
First Patent 2009 - Improved raf inhibitors
Last Trademark 2020 - FORMA THERAPEUTICS
First Trademark 2018 - THE FORMA DIFFERENCE

Industry (Nice Classification)

Latest Inventions, Goods, Services

2024 Invention Inhibiting mutant isocitrate dehydrogenase 1 (midh-1). Patients diagnosed with a cancer harborin...
2023 Invention Pyridin-2(1h)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors. The inv...
Invention Fused pyrrolines which act as ubiquitin-specific protease 30 (usp30) inhibitors. The disclosure ...
Invention Inhibiting cyclic amp-responsive element-binding protein (creb) binding protein (cbp). The prese...
Invention Bromodomain inhibitors for androgen receptor-driven cancers. Methods for treating certain androg...
Invention Tetrahydro-imidazo quinoline compositions as cbp/p300 inhibitors. The present disclosure is dire...
Invention Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,...
Invention Usp1 inhibitors and uses thereof. The present disclosure provides compounds, pharmaceutically acc...
Invention Pyruvate kinase r (pkr) activating compositions. The present disclosure provides crystalline sol...
2022 Invention Treating patients harboring an isocitrate dehydrogenase-1 (idh-1) mutation. Methods of treating ...
Invention Fused pyrrolines which act as ubiquitin-specific protease 30 (usp30) inhibitors. The disclosure r...
Invention Inhibiting ubiquitin-specific protease 1 (usp1). The present disclosure provides compounds for i...
Invention Inhibiting ubiquitin-specific protease 1 (usp1). The present disclosure provides compounds for in...
Invention Inhibiting mutant isocitrate dehydrogenase 1 (midh-1). Patients diagnosed with a cancer harboring...
Invention Inhibiting fatty acid synthase (fasn). The present disclosure is directed to inhibitors of FASN....
Invention Tetrahydro-imidazo quinoline compositions as cbp/p300 inhibitors. The present disclosure is direc...
Invention Inhibiting creb binding protein (cbp). The present disclosure is directed to inhibitors of the C...
2021 Invention Inhibiting ubiquitin specific peptidase 30. The present disclosure relates to chemical entities ...
Invention Purinones as ubiquitin-specific protease 1 inhibitors. The application relates to inhibitors of U...
Invention Inhibiting cyclic amp-responsive element-binding protein (creb) binding protein (cbp). The presen...
Invention Bromodomain inhibitors for androgen receptor-driven cancers. Methods for treating certain androge...
Invention Tetrahydroquinoline compositions as bet bromodomain inhibitors. The present invention relates to...
Invention Activating pyruvate kinase r and mutants thereof. The disclosure provides chemical compounds use...
Invention Novel compounds and compositions for inhibition of fasn. The present invention relates to compou...
2020 Invention Treating patients harboring an isocitrate dehydrogenase 1 (idh-1) mutation. Methods of treating p...
Invention Pyridin-2(1h)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors. The inve...
Invention Inhibiting mutant isocitrate dehydrogenase 1 (midh1). This disclosure relates to compositions and...
Invention Activating pyruvate kinase r. The compound (S)-1-(5-((2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-y...
Invention Pyruvate kinase r (pkr) activating compositions. The present disclosure provides crystalline soli...
Invention Activating pyruvate kinase r. The compound (S)-1-(5-((2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl...
Invention Inhibiting ubiquitin specific peptidase 9x. This disclosure provides methods of treating cancer w...
Invention Inhibiting fatty acid synthase (fasn). The present disclosure is directed to inhibitors of FASN. ...
G/S Pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the trea...
Invention Benzopiperazine compositions as bet bromodomain inhibitors. The present invention relates to inhi...
Invention Inhibiting cyclic amp-responsive element-binding protein (creb). The present disclosure is direc...
2019 Invention Compositions for inhibiting ubiquitin specific protease 1. This disclosure relates to modulating...
Invention Inhibiting ubiquitin specific peptidase 9x. FLT3-ITD and FLT3-TKD are the most frequent mutation...
Invention Inhibiting ubiquitin specific peptidase 9x. The disclosure provides novel chemical compounds use...
Invention Inhibiting ubiquitin specific peptidase 9x. This disclosure provides methods of treating cancer ...
Invention Salts of (s)-(5-cyclobutoxy-2-methyl-6-(1-(piperidin-4-yl)-1h-pyrazol-4-yl)-3,4-dihydroquinolin-1...
Invention Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors. The present disclo...
Invention Inhibiting mutant idh-1. Methods of treating patients diagnosed with cancer harboring an IDH-1 m...
2018 Invention Treatment of glioblastoma with fasn inhibitors. The present disclosure relates to methods of tre...
G/S research and development of pharmaceuticals for others; research and development of pharmaceutica...
G/S chemical compounds for use in bio-pharmaceutical research Pharmaceutical preparations for the tre...